生物活性
VX-809 (Lumacaftor)是用于治疗囊性纤维化（CF）的第二种口服研究候选化合物，通过促进突变型CFTR(F508del-CFTR)的成熟，从而纠正囊性纤维症中常见的CFTR突变，在fisher大鼠甲状腺细胞中EC50为0.1 μM。
靶点信息
| F508del-CFTR (Fisher rat thyroid cells) | | | | |
| 0.1 μM(EC50) | | | | |
化学数据
| 目录号 | A10986 |
| 作用机制 | Modulator (调节剂) |
| M. Wt | 452.4 |
| Formula | C24H18F2N2O5 |
| Purity | >99% |
| Storage | Store lyophilized at -20ºC, keep desiccated.
In lyophilized form, the chemical is stable for36 months.
In solution, store at -20ºC and use within3 monthsto prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. |
| CAS No. | 936727-05-8 |
| Synonyms | VX809 |
| SMILES | CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O |
溶解度
| In vitro (25°C) | DMSO | 88 mg/mL (194.51 mM) |
| Water | Insoluble |
| Ethanol | 6 mg/mL (13.26 mM) |
| In vivo | 30% PEG400+0.5% Tween80+5% propylene glycol | 28 mg/mL |
*<1 mg/ml means slightly soluble or insoluble.
*Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
储备液配制
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
| 0.1 mM | 22.1 mL | 110.52 mL | 221.04 mL |
| 0.5 mM | 4.42 mL | 22.1 mL | 44.21 mL |
| 1 mM | 2.21 mL | 11.05 mL | 22.1 mL |
| 5 mM | 0.44 mL | 2.21 mL | 4.42 mL |
*The above data is based on the productmolecular weight 452.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
